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To the Editor: 
 
Chronic granulomatous disease (CGD), an inherited immunodeficiency resulting from defects in 
the NADPH oxidase complex rendering phagocytes deficient in producing the superoxide anion 
necessary for normal killing of bacterial and fungal microorganisms, leads to severe and recurrent 
infections, inflammatory granulomatous complications and autoimmune diseases.1 It is associated with 
substantial morbidity and premature death. Hematopoietic cell transplantation (HCT) is the only long-
term curative therapy, but utility was historically limited by high rates of graft failure and transplant-
related morbidity and mortality. Transplant survival and graft outcome have improved dramatically over 
the past 10 years, due to reduced toxicity conditioning regimens, detailed graft selection hierarchy, 
superior HLA matching technology, better cell-dosed grafts, greater availability of grafts, improved 
supportive care and more effective anti-microbial therapy. We studied transplant survival post-HCT for 
CGD in a supra-regional immunology transplant center in the United Kingdom.  
 
We report outcomes of patients with CGD who received their first HCT between 1998-2017 at the 
Great North Children’s Hospital, Newcastle upon Tyne, one of two supra-regional transplant centers in 
the UK for children with primary immunodeficiency. Outcomes of interest were overall survival (OS), 
event-free survival (EFS), haematopoietic recovery, toxicities, graft-versus-host disease (GvHD), long-
term survival, graft function, post-transplant immune reconstitution and autoimmune disease post-
transplant. OS was defined as survival from first HCT to last follow-up or death. An event was defined 
as death or second procedure for slipping chimerism. Cox proportional-hazard modelling was used to 
analyse predictors of OS and ES. Variables included for predictor analysis were: year of transplant 
(1998-2007 versus 2008-2017), age at transplant, donor (family versus unrelated donor), conditioning 
(myeloablative conditioning (MAC) versus reduced toxicity conditioning (RTC)), stem cell source 
(marrow versus peripheral blood), total nucleated cell dose (TNC) and CD34 cell dose. Multiple linear 
regression modelling was used to analyse the impact of conditioning, stem cell source and cell doses on 
long-term graft function after first successful HCT. CD3, CD4, CD8, CD19, CD27/CD45RA and CD16/56 
enumeration were measured routinely. All data analyses were performed using STATA version 14.2. 
 
Fifty-five children with CGD were included, none were excluded. A detailed description of 
transplant characteristics is summarized (Table 1). Median age at transplant was 5.3 years (range, 0.6-
18.0). 45 (82%) had X-linked and 10 (18%) autosomal recessive CGD. Twelve (22%) had growth failure 
(defined as weight less than fifth centile for age and gender) at the time of transplant. Of 34 who 
underwent colonoscopy, 31 (91%) had biopsy proven colitis. Four (7%) had biopsy proven 
granulomatous lung inflammation. One had undefined acute necrotising encephalitis.  Prior to 2007 
various conditioning regimens were used, with 21 (38%) patients receiving pharmacokinetically guided 
intravenous (IV) busulfan (Bu) and IV cyclophosphamide with or without serotherapy. From 2007 the 
conditioning regimen was switched to Fludarabine-Treosulfan-Alemtuzumab with post-HCT GvHD 
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prophylaxis using ciclosporin (CSA) and mycophenolate mofetil (MMF) for family and unrelated donors 
(n=24, 44%). Fludarabine-Treosulfan-Thiotepa-ATG-Rituximab was used for CD3 TCR CD19 
depleted haploidentical grafts (n=4, 7%). Of these 4 patients, one received CSA/MMF and the remaining 
3 did not receive any post-HSCT GvHD prophylaxis. The median day to neutrophil and platelet 
engraftment was 16 days (range, 9-37), and 18 days (range, 10-139) respectively. Ten (20%) patients 
had grade II-IV acute GvHD, 5 (9%) had grade III-IV acute GvHD. None had chronic GvHD. Only one 
patient who received Busulfan-based conditioning had veno-occlusive disease. Eleven (20%) had CMV 
viraemia, 5 (9%) adenoviraemia and 5 (9%) EBV viraemia.  
 
The 5-year OS was 89% (95% CI, 67-95%) (Figure 1), rising to 100% for children transplanted at 
5 years of age (n=28) versus 81% (95%CI, 60-92%) for the children >5 years of age (n=27) (p=0.04) 
(Figure 1). The OS was comparable between matched family (88%, 95% CI, 61-97%) and unrelated 
donor transplants (89%, 71-95%) (Figure 3). The 4 haploidentical transplants were successful. Year of 
transplant (p=0.13), conditioning (p=0.58), stem cell source (p=0.57), TNC (p=0.69) and CD34 cell dose 
(p=0.52) were not associated with OS.  All five deaths were due to transplant-related complications. The 
median age at transplant of deceased patients was 10.0 years (range 8.4-18 years). The 5-year EFS for 
the cohort was 77% (95% CI 62-87%). No variables were associated with EFS. All 7 patients with 
slipping chimerism received successful second procedures (3 had unconditioned stem cell boost 
infusion and 4 had fully conditioned second transplant).  
 
Median age of long-term survivors was 14 years (range, 2-36 years) with median duration of 
follow-up of 6.5 years (range, 0.32-19.5). There were no late deaths. None had clinical evidence of 
colitis. Of the 11 survivors who were older than 21 years of age, 6 (55%) had unassisted successful 
pregnancy themselves or with their partners (4 received Busulfan-Cyclophosphamide, 1 Busulfan-
Fludarabine and 1 had Fludarabine-Melphalan). Median donor myeloid chimerism after first successful 
HCT (n=43) was 92%% (range 30-100%). MAC was the only variable associated with higher donor 
myeloid chimerism (p=0.036). MAC (p=0.002) and TNC (p=0.03) were associated with higher donor T-
lymphocyte chimerism (supplemental figure 1 and supplemental table 1). For patients who received 
unconditioned stem cell infusion (n=3), the median myeloid chimerism was 52% (ranges, 30-100%) and 
the median T-lymphocyte chimerism was 26% (range 26% to 100%). For patients who received 
conditioned second transplant (=4), the median myeloid chimerism was higher at 89% (ranges, 30-
100%) and the median T-lymphocyte chimerism was 65% (range 26-100%). Longitudinal immune-
reconstitution results were available for 42 patients of survivors after first successful HCT (supplemental 
figure 2). 
 
The 1- and 5-year cumulative incidence of autoimmune diseases was 9% and 12% respectively, 
significantly less than that reported in a recent study.2 Three (5%) had immune cytopenia in first year 
post-HCT. whilst 3 (5%) had autoimmune endocrinopathy (2 thyroid dysfunction; 1 type 1 diabetes 
mellitus). Two patients with immune haemolysis achieved remission with intravenous immunoglobulin 
and steroid while 1 with immune haemolysis and thrombocytopenia needed additional Rituximab. None 
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had evidence of immune cytopenia at last follow-up. Autoimmune endocrinopathy occurred one year 
post-HCT (median 3.9 years; range, 1.4-7.1). One patient with hypothyroidism received thyroxine 
replacement, 1 with Grave’s disease was treated with radioiodine and 1 with type 1 diabetes mellitus 
received insulin.  
The ability of donor-derived neutrophils to replace recipient’s defective neutrophils makes HCT a 
superior therapy compared to conventional standard of care using antimicrobial therapy.  Previous 
studies demonstrated that non-transplanted children have more serious infections, episodes of surgery, 
poorer growth and reduced quality of life compared to transplanted children.3-5 Estimated survival of 
non-transplanted patients was 88% at 10 years and 55% at the age of 30 years.6 In this study, our 
findings emphasize that HCT performed in an experienced immunology transplant center is safe and 
provides long-term cure for children with CGD. Alternative donors using unrelated and parental 
haploidentical donors are associated with excellent survival comparable to family donors. X-linked 
carrier family donors should be avoided as they have inflammatory and autoimmune symptoms and 
excessive fatigue. 7-9 As young age at HCT is associated with favourable outcome, HCT should be 
performed as early as possible before the onset of disease-related organ damage. In our center, all 
newly diagnosed CGD and newborn CGD are recommended for HCT with either matched donor or 
haploidentical donor if no suitable matched donor available. Family screening and newborn screening 
plays an important role in advancing the transplant care for children with CGD. 
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Table 1: Patient and transplantation characteristics and outcome after first HCT in children with 
CGD (N=55) 
Patient characteristics  
Year of transplant  
1998-2007, n (%) 17 (31) 
2008-2017, n (%) 38 (69) 
Male, n (%) 51 (93) 
Inheritance  
X-linked CGD, n (%) 45 (82) 
Autosomal recessive CGD, n (%) 10 (18) 
Age at transplant, months, median (range) 5.3 (0.6-18.0) 
Donor characteristics  
Type of donor  
Matched family donor, n (%) 20 (36) 
Unrelated donor, n (%) 31 (56) 
Haploidentical donor, n (%) 4 (8) 
Stem cell source  
Marrow, n (%) 29 (53) 
PB, n (%) 24 (43) 
CB, n (%) 2 (4) 
Stem cell dose  
Marrow  
TNC, x 108/kg, median (range) 5.0 (1.6-24.4) 
CD34, x 106/kg, median (range) 4.3 (0.75-53.0) 
PB  
TNC, x 108/kg, median (range) 10.3 (1.2-22.8) 
CD34, x 106/kg, median (range) 8.0 (3.0-29.2) 
Transplant characteristics  
Conditioning regimen  
Myeloablative conditioning (MAC)  
Busulfan-Cyclophosphamide, n (%) 21 (38) 
Fludarabine-Treosulfan-Thiotepa, n (%)  4 (7) 
Reduced toxicity conditioning (RTC)  
Treosulfan-fludarabine, n (%) 24 (45) 
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Busulfan-fludarabine, n (%) 4 (7) 
Treosulfan-cyclophosphamide, n (%) 1 (2) 
Fludarabine-melphalan, n (%) 1 (2) 
Serotherapy  
None, n (%) 9 (16) 
ATG, n (%) 4 (8) 
Alemtuzumab, n (%) 42 (76) 
GVHD prophylaxis  
None, n (%) 3 (5) 
CSA alone, n (%) 2 (4) 
CSA + MTX, n (%) 16 (29) 
CSA + MMF, n (%) 33 (60) 
CSA + steroid (for CB), n (%) 1 (2) 
  
Haematopoietic recovery  
Days to neutrophil recovery, median (range) 16 (9-37) 
Days to platelet recovery, media (range) 18 (10 - 139) 
Transplant-related complications  
Acute GvHD  
Grade II-IV, n (%) 10 (20) 
Grade III-IV, n (%) 5 (9) 
Chronic GvHD2 0 
Veno-occlusive disease, n (%) 1 (2) 
Number of patient received second procedures for slipping chimerism, n (%) 7 (13) 
Number of patients received unconditioned stem cell boost infusion 3 
Myeloid chimerism prior to unconditioned stem cell boost infusion, %, median 
(range) 
17 (15-23) 
Number of patients received fully conditioned second transplant 4 
Myeloid chimerism prior to unconditioned stem cell boost infusion, %, median 
(range) 
11 (0-13) 
Cause of death (n=5)  
Multi-organ failure 2 
Grade IV acute GvHD 1 
Pulmonary haemorrhage 1 
Post-transplant lymphoproliferative disease 1 
Long-term outcome  
ATG: anti-thymocyte globulin (Grafalon) for haploidentical transplant; CB: cord blood; CGD: chronic granulomatous disease; CSA: 
ciclosporin; MMF: mycophenolate mofetil; MTX: methotrexate; PB: peripheral blood; TNC: total nucleated cell dose 
 
 
 
 
 
 
 
